New Metric for Assessing Quality and Managing Risk in Contract Partner Selection

As the pharmaceutical supply chain becomes more and more complex with increasing numbers of outsourced partners supporting the production of innovator companies’ drugs, it has become more important to question how quality should be assessed when searching for contract partners. 

This paper presents the 483 Issuance Rate as a key "new" quality metric during the contract partner selection process.  The paper also offers a discussion of recent regulatory inspection trends and the relationship of these trends to the contract partner selection process.  

Patheon's Privacy Policy
All fields required.
Download Now
Will you be seeking to select a contract manufacturing partner within the next 12 months?
Which drug type(s) will you be seeking a contract manufacturing partner to produce? Check all that apply.
Are you currently researching possible contracting manufacturing partners?